The FDA’s New Tzield Approval Fundamentally Alters Stage 3 Pediatric Type 1 Diabetes Management

Clinician Adoption of AI to Detect LV Systolic Dysfunction in Everyday Practice

AI-powered ECG and ultrasound tools can identify silent left ventricular systolic dysfunction earlier, enabling timely evaluation, targeted treatment, and improved heart failure prevention and outcomes.

How Oral TKIs are Rewriting the Frontline and Pretreated Landscape in HER2-Mutant NSCLC

A new generation of oral HER2-targeted therapies is transforming advanced NSCLC care, delivering durable responses, brain metastasis control, and personalized treatment beyond traditional chemotherapy.

Redefining Biomarker-Driven Care: Telisotuzumab Vedotin-tllv for Advanced Non-Squamous NSCLC

A newly approved c-Met–targeted antibody-drug conjugate offers a precision treatment option for previously treated advanced non-squamous NSCLC, expanding personalized therapy beyond genomic mutations alone.

The FDA’s New Tzield Approval Fundamentally Alters Stage 3 Pediatric Type 1 Diabetes Management

FDA approval of Tzield marks a breakthrough in Type 1 diabetes care, preserving remaining insulin-producing cells and shifting treatment from replacement to disease modification.

Re-evaluating N- Acetylcysteine as a Time-Buying Neuroprotectant in Acute Stroke Care

N-acetylcysteine (NAC) shows promise as a neuroprotective adjunct in acute ischemic stroke, potentially preserving brain tissue, enhancing reperfusion outcomes, and improving recovery during treatment delays.